Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00533598
NCT00533598CompletedPhase 2

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Merck Sharp & Dohme LLC0 sitesStarted: September 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
21 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study

Exclusion Criteria

  • •You are or plan to become pregnant
  • •You have smoked or used nicotine within 6 months of the study
  • •History of abusing alcohol and/or drugs
  • •History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
  • •Have participated in a weight loss program 3 months before the study or during the course of the study

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Terminated
Phase 2
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of ObesityObesity
NCT00367783Pfizer100
Completed
Phase 2
Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)OverweightObesityBody Weight
NCT00642993Merck Sharp & Dohme LLC401
Completed
Phase 2
A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.Obesity
NCT01195792GlaxoSmithKline60
Completed
Phase 3
A Comparative Study of KES524 in Patients With Obesity DiseaseObesity
NCT00165685Eisai Limited
Completed
Phase 4
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese AdolescentsPediatric ObesityChildhood Obesity
NCT02714062VIVUS LLC42
A Study to Determine the Effects of MK0557... | Clinical Trial